Barclays
CCCC icon

Barclays’s C4 Therapeutics CCCC Stock Holding History

Barclays’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$492K Buy
147,776
+73,260
+98% +$273K ﹤0.01% 3472
2026
Q2 		$348K Sell
74,516
-243,361
-77% -$832K ﹤0.01% 3405
2026
Q1 		$836K Buy
317,877
+98,673
+45% +$232K ﹤0.01% 2859
2025
Q4 		$419K Buy
219,204
+176,142
+409% +$417K ﹤0.01% 3939
2025
Q3 		$95.6K Sell
43,062
-2,761
-6% -$6.63K ﹤0.01% 4629
2025
Q2 		$65.5K Sell
45,823
-61,697
-57% -$89.7K ﹤0.01% 4662
2025
Q1 		$172K Sell
107,520
-14,845
-12% -$44.3K ﹤0.01% 4136
2024
Q4 		$441K Sell
122,365
-121,092
-50% -$602K ﹤0.01% 3899
2024
Q3 		$1.39M Buy
243,457
+67,546
+38% +$406K ﹤0.01% 3132
2024
Q2 		$813K Buy
175,911
+122,818
+231% +$732K ﹤0.01% 2727
2024
Q1 		$434K Buy
53,093
+9,478
+22% +$73.5K ﹤0.01% 3678
2023
Q4 		$246K Buy
43,615
+1
+0% +$2 ﹤0.01% 4328
2023
Q3 		$81.1K Buy
43,614
+10,246
+31% +$31.2K ﹤0.01% 3674
2023
Q2 		$91.8K Sell
33,368
-13,995
-30% -$45K ﹤0.01% 3596
2023
Q1 		$149K Sell
47,363
-56,285
-54% -$331K ﹤0.01% 3963
2022
Q4 		$612K Buy
103,648
+28,408
+38% +$236K ﹤0.01% 3176
2022
Q3 		$660K Buy
75,240
+71,244
+1,783% +$740K ﹤0.01% 2514
2022
Q2 		$30K Sell
3,996
-23,647
-86% -$208K ﹤0.01% 4242
2022
Q1 		$670K Buy
+27,643
New +$671K ﹤0.01% 2695

Other funds holding CCCC

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Vienna Insurance Group
Vienna Insurance Group Warsaw, Poland $466M AUM 97.31% 1-Year Est. Return

Barclays's CCCC Position: Q3 2026 in Review

Barclays increased its C4 Therapeutics (CCCC) stake by 98% in Q3 2026, buying an estimated $273K and bringing the position to 147,776 shares worth $492K. The position accounts for ﹤0.01% of the portfolio, ranked #3472.

Barclays first reported a position in CCCC in Q1 2022 and has held it in 19 quarters since. The position peaked at $1.39M in Q3 2024. 38 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

  • Barclays held 147,776 shares of C4 Therapeutics worth $492K as of Q3 2026.
  • Barclays bought 73,260 C4 Therapeutics shares in Q3 2026, an estimated $273K.
  • C4 Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3472 holding.
  • Barclays first reported a position in C4 Therapeutics in Q1 2022 and has held it in 19 quarters since.
  • Barclays's C4 Therapeutics position peaked at $1.39M in Q3 2024.
  • 38 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.